PharmTech News

Articles

Opdivo did not meet primary endpoints in Phase III trials investigating the drug as a monotherapy for untreated advanced non-small cell lung cancer in patients whose tumors expressed PD-L1.

Phase III Trials for Bristol-Myers’ Opdivo Fail to Meet Primary Endpoints

Sanofi Pasteur will deliver the first of more than 65 million influenza vaccines to the United States throughout the 2016–2017 flu season.

FDA Releases First Doses of Sanofi Pasteur Influenza Vaccine for Shipment

Jacobs Engineering Group was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals’ new manufacturing facility in Norton, Massachusetts.

Alnylam Moves Forward on Multi-Product RNAi Facility

The cyclin dependent kinase inhibitor received Breakthrough Therapy Designation as a first line treatment for advanced breast cancer.

Ribociclib Receives Breakthrough Therapy Designation

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

FDA approved Natco and Alvogen’s generic Tamiflu to treat and prevent influenza.

FDA Approves First Generic Version of Tamiflu

The collaboration will focus on methods to eradicate cancer stem cells

Plasticell and National University of Ireland Form Stem-Cell Pact

Galvani Bioelectronics will be based in Stevenage, UK, and headed by Kris Famm, GSK's vice president of bioelectronics R&D

GSK, Verily to Set Up Bioelectronics Joint Venture

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Amgen discussed the drug-delivery approaches to two of its biologics in a recent second-quarter earnings call.

Amgen: Neulasta Safe for Now; Dose Accuracy of Erenumab a New Focus

The move follows a warning from FDA wherein FDA cited ALK-Abello with numerous manufacturing violations.

Merck Returns Rights to Allergy Tablets Back to ALK-Abello

On July 27, 2016, John C. Lechleiter, PhD, chairman, president, and CEO of Eli Lilly, announced his retirement from the company. This decision is effective December 31, 2016, however, Lechleiter will remain on the company’s board of directors until May 31, 2017 as a non-executive chairman. Lechleiter joined the company in 1979 as a senior organic chemist in process R&D. He has served as CEO of Eli Lilly since April 2008.

Bio/Pharma News